The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors.
about
Translational Research and Functional Changes in Voiding Function in Older AdultsThe new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitorsA review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunctionEffects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options.Impact of lower urinary tract symptoms/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile functionAre phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: A systematic review and network meta-analysis.Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis.Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil.Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management.Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.Tadalafil - a therapeutic option in the management of BPH-LUTS.Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction?Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms.An update on sexual function and dysfunction in women.How does lower urinary tract dysfunction affect sexual function in men and women? ICI-RS 2015-Part 1.LUTS in pelvic ischemia: a new concept in voiding dysfunction.How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI-RS 2015-Part 2.The relationship of salivary testosterone and male sexual dysfunction in opioid-associated androgen deficiency (OPIAD).Prevalence of male pelvic dysfunction: results from the Turkish society of andrology male sexual health study group.[The sexual health of men from a sexual-medical perspective].Residual renal function and erectile dysfunction in patients on hemodialysis.Lower urinary tract symptoms in patients with liver cirrhosis.Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study.Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function.Lower urinary tract symptoms (LUTS) - an independent risk factor for cardiovascular disease (CVD).Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms
P2860
Q26782134-79DD107F-AE03-44F7-B662-D0A69EB6004BQ27025700-0859847C-F4D6-4276-B3FD-B702E67597ADQ33744285-F325AE94-7D52-4E31-9177-B6EAD3335833Q34114694-C0067570-BE37-464B-9544-2285E386EDF1Q34567905-8209DB60-540F-44D5-B2AE-62E571887609Q35050805-64435269-258D-4823-8DAA-A2DDF9C3CAFFQ35924409-9C581890-5BA5-42CE-83C3-EF676397AD5BQ36054510-4460A9FA-E495-48B4-8A69-E9EEDD9D54C4Q37108885-E2371638-4820-4507-A1A8-A1FC68D22961Q37466573-6203C9AF-54BA-4F7A-8A63-3F96408182C3Q37833959-AE2398A5-70C7-46F7-811F-A1B5C8797B28Q37877132-46AE3417-E076-4DB7-A9ED-1D5C16D3B03BQ38093143-ECD84F05-4266-4C4E-B24F-99DC58A3B357Q38171532-D173C1DE-58A9-44F3-BB8B-FF5F6FF26C75Q38220350-00D2D2B2-7BB3-4D93-B17D-BBBEF7747A65Q38262087-2B7656DF-AE81-44E2-9E68-A9B1B3C7D304Q38454048-E9954769-171A-4CC6-AD78-C5F139E6BB83Q38690697-CFDBA0B0-444B-468C-9B27-1F63694E3F92Q38704953-0A5A0D6E-1C01-466F-A754-5A4052C32E11Q38819020-B59B4F39-5B53-49D3-AEAB-D07AF2E2BA52Q39280821-91970DF6-7272-4D8A-B7CE-64960DF37596Q43474566-901E3628-178F-44E4-9486-7C3868082DBFQ43824041-CD711C5A-2692-4A09-8521-F98A376269F5Q53047154-AAE3A8E4-07AE-4DED-848F-E0EFF3E72E25Q53090397-47B1BBAF-FA39-492C-BAC7-B87304938E2CQ53117877-2F5E51BB-9BC6-4BB1-9354-97F8D87A4F4CQ53163585-17640F2F-89B9-4203-A3E7-33C498A1D79AQ53318022-A6FF76B8-692B-4515-9B4E-084894662A56Q57595115-40044B09-4C98-435B-924C-48A68AEEFF68
P2860
The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The relationship between erect ...... odiesterase type 5 inhibitors.
@en
The relationship between erect ...... odiesterase type 5 inhibitors.
@nl
type
label
The relationship between erect ...... odiesterase type 5 inhibitors.
@en
The relationship between erect ...... odiesterase type 5 inhibitors.
@nl
prefLabel
The relationship between erect ...... odiesterase type 5 inhibitors.
@en
The relationship between erect ...... odiesterase type 5 inhibitors.
@nl
P1433
P1476
The relationship between erect ...... odiesterase type 5 inhibitors.
@en
P2093
Kevin T McVary
Tobias S Köhler
P356
10.1016/J.EURURO.2008.08.062
P407
P577
2008-09-04T00:00:00Z